INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. due to allegations of securities fraud and unlawful business practices, following a significant drop in stock price after negative feedback from the FDA regarding its investigational gene therapy AMT-130 [1][1][1] Company Summary - uniQure N.V. is facing a class action lawsuit related to potential securities fraud involving its officers and directors [1] - The lawsuit is prompted by a press release from November 3, 2025, where uniQure announced that the FDA no longer believes that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application (BLA) submission [1][1] - Following this announcement, uniQure's stock price fell by $33.40 per share, or 49.34%, closing at $34.29 per share [1][1][1] Industry Context - Pomerantz LLP, the law firm handling the class action, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [1][1]